mhurhangee/ep-ind-claims huggingface dataset:
A coating comprising the reaction product of a reaction system, the reaction system comprising: at least one prepolymer having isocyanate functional groups, wherein the prepolymer comprises the reaction product of a prepolymer reaction mixture comprising: at least one isocyanate; at least one polyol having an hydroxyl functionality of between 2 and 6; and at least one silicone surfactant having at least one isocyanate reactive moiety; a sodium silicate solution at least one isocyanate reactive component having at least one of a hydroxyl and an amine functionality of between 2 and 4; at least one intumescent filler; at least one filler; and optionally a suspension agent. at least one prepolymer having isocyanate functional groups, wherein the prepolymer comprises the reaction product of a prepolymer reaction mixture comprising: at least one isocyanate; at least one polyol having an hydroxyl functionality of between 2 and 6; and at least one silicone surfactant having at least one isocyanate reactive moiety; at least one isocyanate; at least one polyol having an hydroxyl functionality of between 2 and 6; and at least one silicone surfactant having at least one isocyanate reactive moiety; a sodium silicate solution at least one isocyanate reactive component having at least one of a hydroxyl and an amine functionality of between 2 and 4; at least one intumescent filler; at least one filler; and optionally a suspension agent.
A tablet comprising the following (i)-(iii): (i) 1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1H-benzimidazole-2-carboxamide or a salt thereof, (ii) 30 to 50 wt% of crystalline cellulose in the tablet (of the weight of one tablet), and (iii) 5 to 20 wt% of low-substituted hydroxypropylcellulose in the tablet (of the weight of one tablet). (i) 1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1H-benzimidazole-2-carboxamide or a salt thereof, (ii) 30 to 50 wt% of crystalline cellulose in the tablet (of the weight of one tablet), and (iii) 5 to 20 wt% of low-substituted hydroxypropylcellulose in the tablet (of the weight of one tablet).
An isolated antibody that binds to human PD1, wherein the antibody i) comprises a VH sequence of SEQ ID NO:57 and a VL sequence of SEQ ID NO:58, or ii) comprises a VH sequence of SEQ ID NO:57 and a VL sequence of SEQ ID NO:59, or iii) comprises a VH sequence of SEQ ID NO:57 and a VL sequence of SEQ ID NO:60, or iv) comprises a VH sequence of SEQ ID NO:57 and a VL sequence of SEQ ID NO:61. i) comprises a VH sequence of SEQ ID NO:57 and a VL sequence of SEQ ID NO:58, or ii) comprises a VH sequence of SEQ ID NO:57 and a VL sequence of SEQ ID NO:59, or iii) comprises a VH sequence of SEQ ID NO:57 and a VL sequence of SEQ ID NO:60, or iv) comprises a VH sequence of SEQ ID NO:57 and a VL sequence of SEQ ID NO:61.
System for conveying objects comprising an object conveyor which extends between an upstream end and a downstream end, and a motor-driven shuttle carriage having an object-carrying plate, said carriage being designed to dock at the downstream and upstream ends of the conveyor so as to transfer an object between the carriage and the conveyor, the conveyor being a gravity conveyor under which a ramp extends, the carriage being capable of moving under the conveyor and comprises a lever which is vertically movable with respect to the plate, said lever being designed to interact with the ramp when the carriage moves under the conveyor such that by following the ramp, the lever moves between a retracted position in which it disappears under the conveyor and a deployed position in which it projects above the conveyor so as to cause an object to move on the conveyor, characterized in that the conveyor comprises at its downstream end a first retractable stop which is designed to block an object at the downstream end of the conveyor, and in that the carriage comprises a thrust member which is designed to interact with the first stop when it moves under the downstream end of the conveyor so that, when it makes contact with the thrust member, the first stop is pushed to the sides of the conveyor to allow the object to be transferred onto the plate of the carriage.
A potential transformer isolating device, comprising a swinging rod (11, 31) and a guide pole (14, 34), wherein the isolating device is capable of connecting the potential transformer to a primary loop high-voltage end and the isolating device is capable of contacting the housing of the transformer, and the potential transformer isolating device further comprises a compression device (13, 33); the guide pole (14, 34) has a guide-pole guide end (142, 342) and an arc-shaped guide-pole connecting end (141, 341); when the guide-pole connecting end (141, 341) is under the action of an external force, the guide pole moves along a direction of the swinging rod (11, 31) and compresses the compression device (13, 33); when the external force is removed, the guide pole (14, 34) is reset under an acting force of the compression device (13, 33); the guide-pole connecting end further being configured to reach a smooth connection with the housing of the transformer for implementing reliable insulating and grounding functions.
A process to produce an edible oil with a polyunsaturated fatty acid concentration between 30 w/w % and 90 w/w %, by selective crystallization and removal of saturated and mono-unsaturated fatty acids from the oil, carried out in the presence of urea, a phase transfer catalyst, and a polar solvent, wherein the phase transfer catalyst is present at a concentration between 5 w/w % and 20 w/w % of the free fatty acid oil and is selected from adipic acid, 8-crown-6 ether, benzyl trimethylammonium chloride, dodecyl trimethylammonium chloride, cetyl trimethylammonium chloride and hexadecyl tributylphosphonium chloride.
A structural arrangement for a textile strap with fluorescent coating, wherein the textile strap is made of at least one layer of synthetic-based fibres, it is preferably belt-shaped, and has a plastic-containing coating covering 100% of its surface, furthermore a fluorescent dye/pigment is mixed into the material of the coating characterized in that at least one synthetic-based fibre with a melting point equal to or lower than that of the coating, melting together with the coating, and load-bearing synthetic fibres with a melting point higher than that of the coating are incorporated into the textile strap, furthermore natural-based fibres with low elongation are incorporated into the textile strap and the load-bearing synthetic fibres the synthetic fibres melting together with the coating and the natural-based fibres are incorporated into the textile strap as warp yarns, kept together by the weft yarns, and the surface of the coating is sandblasted and/or textured, furthermore in the textile strap the load-bearing synthetic fibres, the synthetic fibres melting together with the coating and the natural-based fibres are arranged symmetrically on both sides of the axis line.
Therapy means comprising a blood pressure meter comprising an inflatable cuff which can be placed around the patient's upper arm, for non-invasive blood pressure measurements and a controller for controlling the times of blood pressure measurement and for controlling the blood pressure as a function of the determined blood pressure values, characterized in that the blood pressure measurement is omitted at some times provided by controller and is substituted by hypothetical values gathered from a former blood pressure curve determined during a therapy session which is stored in a data storage.
A T cell therapy and an immunomodulatory compound for use in a method of treating cancer, wherein the method comprises: (a) administering a T cell therapy to a subject having a disease or condition that is cancer, wherein the T cell therapy is or comprises genetically engineered cells expressing a recombinant receptor that specifically binds to an antigen, wherein the recombinant receptor is a chimeric antigen receptor, and wherein the CAR comprises an extracellular domain comprising an antigen-binding domain that specifically binds to a tumor antigen, a spacer, and an intracellular signaling region; and (b) administering to the subject an immunomodulatory compound, wherein said immunomodulatory compound is thalidomide (2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3 -dione) or an analog or derivative of thalidomide, and wherein the immunomodulatory compound: (i) binds to cereblon (CRBN) and/or to the CRBN E3 ubiquitin-ligase complex, and (ii) enhances the degradation of both Ikaros (IKZF1) and Aiolos (IKZF3); wherein initiation of administration of the immunomodulatory compound is carried out 7 to 21 days after initiation of administration of the T cell therapy, and wherein the immunomodulatory compound is administered orally. (a) administering a T cell therapy to a subject having a disease or condition that is cancer, wherein the T cell therapy is or comprises genetically engineered cells expressing a recombinant receptor that specifically binds to an antigen, wherein the recombinant receptor is a chimeric antigen receptor, and wherein the CAR comprises an extracellular domain comprising an antigen-binding domain that specifically binds to a tumor antigen, a spacer, and an intracellular signaling region; and (b) administering to the subject an immunomodulatory compound, wherein said immunomodulatory compound is thalidomide (2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3 -dione) or an analog or derivative of thalidomide, and wherein the immunomodulatory compound: (i) binds to cereblon (CRBN) and/or to the CRBN E3 ubiquitin-ligase complex, and (ii) enhances the degradation of both Ikaros (IKZF1) and Aiolos (IKZF3); (i) binds to cereblon (CRBN) and/or to the CRBN E3 ubiquitin-ligase complex, and (ii) enhances the degradation of both Ikaros (IKZF1) and Aiolos (IKZF3); wherein initiation of administration of the immunomodulatory compound is carried out 7 to 21 days after initiation of administration of the T cell therapy, and wherein the immunomodulatory compound is administered orally.
A boring head comprising a cutting insert, such that the boring head comprises, in its body, at least one device for allowing the displacement of a liquid, the device comprising at least two openings on the surface of the boring head and arranged at the level of the insert, wherein the cutting insert is mounted displaceably on the boring head, characterised in that the at least two openings are disposed along an axis substantially parallel to the axis of displacement of the cutting insert. such that the boring head comprises, in its body, at least one device for allowing the displacement of a liquid, the device comprising at least two openings on the surface of the boring head and arranged at the level of the insert, wherein the cutting insert is mounted displaceably on the boring head, characterised in that the at least two openings are disposed along an axis substantially parallel to the axis of displacement of the cutting insert.
A recombinant adeno-associated virus (rAAV) particle comprising a vector encoding R-Spondin 3 (RSPO3) for use in a method for treating myocilin (MYOC) glaucoma in a mammal, wherein said method comprises administering said rAAV particle to the eye of the mammal, and wherein the RSPO3 is operably linked to a promoter, wherein: (i) the promoter is capable of expressing the R-Spondin 3 (RSPO3) in the eye of the mammal; and/or (ii) the promoter is capable of expressing the R-Spondin 3 (RSPO3) in cells of the trabecular meshwork. (i) the promoter is capable of expressing the R-Spondin 3 (RSPO3) in the eye of the mammal; and/or (ii) the promoter is capable of expressing the R-Spondin 3 (RSPO3) in cells of the trabecular meshwork.
A method for utilizing a block chain infrastructure to define a trusted user circle comprising at least two nodes of a plurality of nodes, the method comprising: receiving, by a first node, notification information identifying the trusted user circle comprising the first node and a second node, wherein the first node and the second node are configured to define a private block chain; and maintaining private block chain data within the trusted user circle according to pre-defined settings, wherein the private block chain data is divided between nodes of the trusted user circle based on the pre-defined settings. receiving, by a first node, notification information identifying the trusted user circle comprising the first node and a second node, wherein the first node and the second node are configured to define a private block chain; and maintaining private block chain data within the trusted user circle according to pre-defined settings, wherein the private block chain data is divided between nodes of the trusted user circle based on the pre-defined settings.
A coolant pump assembly having an electric coolant pump for a motor vehicle and an engine component and/or a body part, comprising a multi-part pump housing having a coolant inlet and a coolant outlet, wherein in said pump housing an electric drive unit is arranged and wherein said pump housing comprises a fastening assembly (18, 20, 26, 28, 32, 50) via which said coolant pump is adapted to be detachably connected in the engine compartment to the engine component and/or the body part, wherein said fastening assembly comprises at least one screw connection (32, 50) and at least one interlocking connection (18, 26; 20, 28), characterized in that the at least one interlocking connection (18, 26, 20, 28) and the at least one screw connection (32, 50) comprising a common joining direction.
An isolated or purified nucleic acid molecule that (a) encodes an LMNA-NTRK1 fusion polypeptide comprising (i) one or more of encoded exons 1-5 of SEQ ID NO: 20 and (ii) encoded exons 12-17 of SEQ ID NO: 22; (b) encodes a LMNA-NTRK1 fusion which comprises an amino acid sequence at least 85% identical (i) to amino acid sequence SEQ ID NO: 20, or a fragment thereof comprising one or more of encoded exons 1-5 of SEQ ID NO: 20, and (ii) to amino acid sequence SEQ ID NO: 22, or a fragment thereof comprising encoded exons 12-17 of SEQ ID NO: 22, and has a tyrosine kinase activity; (c) is an LMNA-NTRK1 fusion nucleic acid molecule comprising (i) one or more of exons 1-5 of SEQ ID NO: 19 and (ii) exons 12-17 of SEQ ID NO: 21; or (d) is an LMNA-NTRK1 fusion which comprises a nucleic acid molecule having a nucleotide sequence at least 85% identical (i) to nucleotide sequence SEQ ID NO: 19, or a fragment thereof comprising one or more of exons 1-5 of SEQ ID NO: 19, and (ii) to nucleotide sequence SEQ ID NO: 21, or a fragment thereof comprising exons 12-17 of SEQ ID NO: 21, and encoding an LMNA-NTRK1 polypeptide having a tyrosine kinase activity; wherein the LMNA-NTRK1 fusion includes a LMNA-NTRK1 fusion junction. (a) encodes an LMNA-NTRK1 fusion polypeptide comprising (i) one or more of encoded exons 1-5 of SEQ ID NO: 20 and (ii) encoded exons 12-17 of SEQ ID NO: 22; (b) encodes a LMNA-NTRK1 fusion which comprises an amino acid sequence at least 85% identical (i) to amino acid sequence SEQ ID NO: 20, or a fragment thereof comprising one or more of encoded exons 1-5 of SEQ ID NO: 20, and (ii) to amino acid sequence SEQ ID NO: 22, or a fragment thereof comprising encoded exons 12-17 of SEQ ID NO: 22, and has a tyrosine kinase activity; (c) is an LMNA-NTRK1 fusion nucleic acid molecule comprising (i) one or more of exons 1-5 of SEQ ID NO: 19 and (ii) exons 12-17 of SEQ ID NO: 21; or (d) is an LMNA-NTRK1 fusion which comprises a nucleic acid molecule having a nucleotide sequence at least 85% identical (i) to nucleotide sequence SEQ ID NO: 19, or a fragment thereof comprising one or more of exons 1-5 of SEQ ID NO: 19, and (ii) to nucleotide sequence SEQ ID NO: 21, or a fragment thereof comprising exons 12-17 of SEQ ID NO: 21, and encoding an LMNA-NTRK1 polypeptide having a tyrosine kinase activity; wherein the LMNA-NTRK1 fusion includes a LMNA-NTRK1 fusion junction.
A fusion protein comprising at least two amino acid sequences, wherein said two amino acid sequences consist of a first amino acid sequence having at least 90 % sequence identity with an amino acid sequence as shown in SEQ ID NO:2, fused to a second amino acid sequence having at least 90 % sequence identity with an amino acid sequence as shown in SEQ ID NO:4, wherein said fusion protein is capable of eliciting protective immunity against group B Streptococcus.
A method for monitoring at least one stability parameter of a loading crane mounted on a vehicle by means of a device, wherein during crane operation the vehicle is supported on the ground by means of wheels (3a, 3b) and by means of support elements separate from the wheels (3a, 3b), characterized in that both contributions of the wheels (3a, 3b) and contributions of the support elements to a magnitude of the stability parameter are detected and said magnitude is compared to at least one predetermined limit value, wherein the device comprises wheel and support element measuring devices, by which both contributions of the wheels (3a, 3b) and contributions of the support elements to the magnitude of the at least one stability parameter can be detected, wherein the device comprises a control and regulating unit, to which measuring signals of the wheel and support element measuring devices can be fed, wherein a magnitude of the at least one stability parameter can be detected and can be compared to at least one predetermined limit value by the control and regulating unit, and in that a number (a) of the wheels (3a, 3b) and support elements, by means of which the vehicle is supported on the ground, is monitored as stability parameter, and in that a force-stability coefficient (S F) is monitored as stability parameter, wherein the force-stability coefficient (S F) is calculated from support forces ( F i) provided by means of the wheels (3a, 3b) and the support elements, wherein the force stability coefficient (S F) is calculated in accordance with the following formula: S F = ∑ i = 1 a ges F i ∑ i = 1 a min − 1 F i, max, wherein (a ges) specifies a total number of the wheels (3a, 3b) and support elements, (a min) specifies a predetermined minimum number of wheels (3a, 3b) and support elements, by means of which the vehicle must be supported at least on the ground, and (F i,max) specifies the (a min -1) greatest support forces.
A method implemented by a network device in a communication network to protect a vehicle from insertion of malicious operations, the method comprising: establishing, by a virtual vehicle entity executed by the network device, a communication session with a requestor, the virtual vehicle entity operating as a proxy for the vehicle, wherein a location of the network device is in proximity to the vehicle; receiving, by the virtual vehicle entity, status information from the vehicle via a radio access network; querying, by the virtual vehicle entity, a deep learning platform with the status information and a message from the requestor; and dropping, by the virtual vehicle entity, the message from the requestor in response to the deep learning platform indicating the message is malicious. establishing, by a virtual vehicle entity executed by the network device, a communication session with a requestor, the virtual vehicle entity operating as a proxy for the vehicle, wherein a location of the network device is in proximity to the vehicle; receiving, by the virtual vehicle entity, status information from the vehicle via a radio access network; querying, by the virtual vehicle entity, a deep learning platform with the status information and a message from the requestor; and dropping, by the virtual vehicle entity, the message from the requestor in response to the deep learning platform indicating the message is malicious.
An antigenic molecule, photosensitizing agent, checkpoint inhibitor and a TLR3 ligand for use in prophylaxis or therapy, wherein the antigenic molecule is a peptide, the photosensitizing agent is selected from a sulfonated tetraphenylporphine, a sulfonated tetraphenylchlorin and a sulfonated tetraphenylbacteriochlorin, the checkpoint inhibitor is an antibody selected from anti-CTLA4 and/or anti-PD-1, and the TLR3 ligand is a double stranded RNA molecule. the antigenic molecule is a peptide, the photosensitizing agent is selected from a sulfonated tetraphenylporphine, a sulfonated tetraphenylchlorin and a sulfonated tetraphenylbacteriochlorin, the checkpoint inhibitor is an antibody selected from anti-CTLA4 and/or anti-PD-1, and the TLR3 ligand is a double stranded RNA molecule.
A method for providing power optimization in a home automation system, comprising: monitoring user activity related to a room of a structure managed by the home automation system; maintaining a device of the home automation system that is associated with the room in a low-power inactive state while there is no user activity related to the room, the device being an audio/video, A/V, device, a lighting device, a heating ventilation and cooling, HVAC, device, a security device or an interconnection device; in response to user activity related to the room, transitioning the device preemptively from the low-power inactive state to an in-use state, the device being transitioned to the in-use state absent a current attempt to use the device by a user or another device of the home automation system; and in response to expiration of a timer since a last use of the device or the transition to the in-use state was made and no actual use occurred, exiting the in-use state. monitoring user activity related to a room of a structure managed by the home automation system; maintaining a device of the home automation system that is associated with the room in a low-power inactive state while there is no user activity related to the room, the device being an audio/video, A/V, device, a lighting device, a heating ventilation and cooling, HVAC, device, a security device or an interconnection device; in response to user activity related to the room, transitioning the device preemptively from the low-power inactive state to an in-use state, the device being transitioned to the in-use state absent a current attempt to use the device by a user or another device of the home automation system; and in response to expiration of a timer since a last use of the device or the transition to the in-use state was made and no actual use occurred, exiting the in-use state.
A delivery system for supplying one or more additives to a fluid comprising an additive gel, a filter comprising a housing, and a fluid/gel chemistry exchange region located outside of the region of the filter housing that experiences the direct flow of the fluid where the fluid contacts the gel; wherein the filter housing comprises a body and a cap, where the cap comprises an inner wall and an outer wall, wherein the inner wall forms a cylinder within the filter cap that connects to the outer wall at one end of the cap and is open at the other end of the cap, and wherein the inner wall and outer wall form an annular space along the outer wall of the cap and wherein the additive gel is placed within the annular space; and wherein the cap fastens to the body of the filter forming the filter housing such that the cap is located on the crown of the filter housing at the opposite end of the filter that mounts onto a filter using device.